The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma

The signaling lymphocytic activation molecule family 3 (SLAMF3) is highly expressed on plasma cells from patients with multiple myeloma (MM) and induces high malignant potential by ERK signaling mediated via the interaction with adaptor proteins SHP2 and GRB2. This study focused on the single-nucleo...

Full description

Saved in:
Bibliographic Details
Published in:Experimental hematology 2020-10, Vol.90, p.72-79
Main Authors: Ishibashi, Mariko, Sunakawa-Kii, Mika, Kaito, Yuta, Kinoshita, Ryosuke, Asayama, Toshio, Kuribayashi, Yasuko, Inokuchi, Koiti, Morita, Rimpei, Tamura, Hideto
Format: Article
Language:English
Subjects:
Alleles
Animals
Cell Line, Tumor
Disease-Free Survival
Female
Genotype
Humans
Japan - epidemiology
Male
MAP Kinase Signaling System - genetics
Mice
Multiple Myeloma - genetics
Multiple Myeloma - metabolism
Multiple Myeloma - mortality
Neoplasm Proteins - genetics
Neoplasm Proteins - metabolism
Polymorphism, Single Nucleotide
Signaling Lymphocytic Activation Molecule Family - genetics
Signaling Lymphocytic Activation Molecule Family - metabolism
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The signaling lymphocytic activation molecule family 3 (SLAMF3) is highly expressed on plasma cells from patients with multiple myeloma (MM) and induces high malignant potential by ERK signaling mediated via the interaction with adaptor proteins SHP2 and GRB2. This study focused on the single-nucleotide polymorphism (SNP) of the SLAMF3 gene (rs509749, 1804A>G, M602V) in MM. The SNP G allele was a major type, and the frequencies of the GG, GA, and AA genotypes were 61.8%, 29.4%, and 8.8%, respectively, in patients with MM, which was almost the same as in healthy the control group in the Japanese population. Interestingly, patients with GG genotypes had significantly shorter overall survival times than patients with GA/AA genotypes. Consistent with those results, SLAMF3-overexpressing KMS-34 cells with the G allele (V602) had higher cell proliferation potential and were more resistant to anti-MM agents than those with the A allele (M602). When those cells were subcutaneously inoculated into NOG mice, tumor sizes in mice receiving V602 cells rapidly increased, and survival was significantly shorter than in mice injected with M602 cells. Furthermore, SLAMF3 V602 molecules bound more tightly to SHP2 and GRB2, with increased SHP2 and ERK phosphorylation compared with M602 cells. The mRNA expression of cell cycle-related genes (CCND1 and CCNE1) and anti-apoptotic genes (BCL2L and p21) was increased in V602 cells compared with M602 cells. The results thus suggested that the G allele of SLAMF3 SNP rs509749 may be associated with MM disease progression. •The SLAMF3 rs509749 GG genotype predominates in Japanese patients with MM and the control group.•GG genotype patients with MM had shorter overall survival time than the GA/AA group.•SLAMF3 V602-expressing MM cells had more aggressive behavior than M602 cells.•Affinity for SHP2 and GRB2 induced ERK phosphorylation in SLAMF3 V602 cells.•ERK signaling activation promoted malignant progression in SLAMF3 V602 cells.
ISSN:0301-472X
1873-2399
DOI:10.1016/j.exphem.2020.08.006